Ascendis Pharma intros Skytrofa

Skytrofa is the first and only FDA-approved, once-weekly treatment for pediatric growth hormone deficiency.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Ascendis Pharma is introducing Skytrofa (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone.

Skytrofa is available by prescription and distributed through a network of specialty pharmacies.

[Read more: Retailers build out their specialty offerings]

“Skytrofa offers patients, caregivers, and physicians the potential to replace daily somatropin injections that have been the standard of care for more than 30 years,” said Jan Mikkelsen, Ascendis Pharma’s President and CEO. “As the first and only FDA-approved once-weekly therapy for pediatric growth hormone deficiency, Skytrofa represents one of the most important innovations for these patients in decades.”

[Read more: ChemoCentryx selects Amber Specialty to dispense Tavneos]

Ascendis Pharma also has launched the Ascendis Signature Access Program, a personalized patient support program dedicated to working with families, caregivers, and physicians from decision to treat through long-term therapy adherence. The program is staffed by nurses and offers a full suite of services including, but not limited to, prior authorization support, out of pocket assistance, and training on proper injection procedures.